Biotech Values

[DewDiligence]

> MNTA – That would be precedent setting, settling with competitors that haven't even been approved…<

True, but this case is unlike any that’s come before.

>…and likely won't…<

I’m not sure I fully agree on this point. The TEVA and Amphastar applications may be dead it the water, but the large amount of elapsed time does not necessarily assure this. That’s one corollary of the Omnitrope decision.